Evidence map›Paper›PMID 42236641›Full record

ArticleInfectious diseases and therapy2026

Micafungin Sequestration and Late Release During Continuous Renal Replacement Therapy with Polyacrylonitrile- and Polysulfone-Derived Filters.

Julien Massol, Valentin Maulet, Vincent Jullien, Solange Corriol-Rohou, Jean-Herlé Raphalen, Frédéric J Baud, Lionel Lamhaut, Olivier Lortholary

Abstract read
In one paragraph

Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Julien MassolDepartment of Cardiac Anesthesiology and Intensive Care, Necker University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. julien.massol@aphp.fr.ORCID http://orcid.org/0009-0004-5767-4441
Valentin MauletNeckEpur SAS, Versailles, France.
Vincent JullienUnité Fonctionnelle de Pharmacologie, GHU Paris Seine Saint-Denis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne Paris Nord, Bondy, France.
Solange Corriol-RohouAstraZeneca R&D Cambridge, Cambridge, UK.
Jean-Herlé RaphalenSAMU de Paris and Intensive Care Unit, Necker University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Frédéric J BaudNeckEpur SAS, Versailles, France.
Lionel LamhautNeckEpur SAS, Versailles, France.
Olivier LortholaryDepartment of Tropical and Infectious Diseases, Necker University Hospital, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdsorption within continuous renal replacement therapy (CRRT) circuits may reduce exposure to echinocandins. Because micafungin is highly protein bound, the behavior of its unbound fraction during CRRT remains difficult to characterize. We assessed unbound micafungin disappearance from a central compartment and late release/desorption in a protein-free in vitro CRRT model.

methodsMicafungin stability was assessed in a 5-L bag of Hemosol™ B0 over 8 h. In the NeckEpur model, a 5-L protein-free central compartment was circulated at 200 mL/min for 6 h through either a polyacrylonitrile hemofilter (ST™150; post-dilution continuous veno-venous hemofiltration [CVVH], 2.5 L/h) or a polysulfone hemofilter (AV™1000). For AV™1000, one run used CVVH (2.5 L/h) and one used continuous veno-venous hemodiafiltration (CVVHDF; dialysis 1.5 L/h plus filtration 1.0 L/h). Initial micafungin concentrations in the central compartment were 2.18 mg/L or approximately 6.8 mg/L. Concentrations were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with a lower limit of quantification (LLOQ) of 0.1 mg/L. Apparent central-compartment clearance (Cl_CC), sieving coefficient (Sc), and extraction coefficient (EC) were used to describe disappearance from the circuit, filtration, and late release. Sensitivity analyses replaced values < LLOQ by LLOQ/2 or LLOQ/√2. Segmental sampling and within-filter mass balance were used descriptively to localize loss within the extracorporeal system.

resultsMicafungin was stable in Hemosol™ B0 over 8 h (- 5.2 ± 0.5%). With ST™150 at 2.18 mg/L, C_CC reached the LLOQ by 200 min and was below the LLOQ thereafter; apparent Cl_CC was approximately 6 L/h, effluent concentrations were not measurable, and limited late release was estimated over 120-200 min. With ST™150 at approximately 6.8 mg/L, elimination from the central compartment was 92 ± 4% at 6 h (apparent Cl_CC 4.9 ± 0.2 L/h), with within-filter contributions from measurable effluent removal (54 ± 6%) and non-effluent loss (46 ± 6%); small late release was compatible with negative EC values during 180-360 min. For AV™1000, two exploratory runs-one CVVH and one CVVHDF-showed rapid disappearance from the central compartment, with C_CC below the LLOQ by 120 min, no measurable effluent concentrations, and no negative EC values. Sensitivity analyses for values < LLOQ changed the numerical Cl_CC estimates but not the overall pattern. Segmental concentration data and within-filter mass-balance analysis localized the dominant loss to the filter module, with only limited upstream inlet-segment contribution.

conclusionIn this exploratory protein-free in vitro model, unbound micafungin rapidly disappeared from the CRRT circuit with both tested filter systems. ST™150 showed measurable effluent removal at higher concentrations and limited late release, whereas both exploratory AV™1000 runs showed rapid disappearance without detectable late release. Segmental concentration data and within-filter mass-balance analysis localized the dominant loss to the filter module, with only limited upstream inlet-segment contribution. These findings characterize unbound micafungin-circuit interactions under the tested conditions; their clinical translation will depend on in vivo protein binding and rebinding kinetics.

Indexed as

AdsorptionContinuous renal replacement therapyEchinocandinsExtraction coefficientHemodiafiltrationHemofiltrationIn vitro modelMicafunginSequestration

Identifiers

PMID42236641
PMCPMC13279833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.